Entera Bio (ENTX): Aggregate Business Value
Entera Bio Ltd. (ENTX) specializes in developing tablet versions of injectable osteoporosis treatments to improve therapy convenience. The company's research center is located in Israel, while the production of trial batches is delegated to external CDMO partners. Strong interest in replacing injections with oral forms opens the door to licensing deals with global tech giants. The current enterprise value of Entera Bio Ltd. (ENTX) is 479.41, as clearly illustrated by the price chart below.
Entera Bio (ENTX) - metric breakdowns and financial figures
Enterprise Value reflects the total cost of ownership for Entera Bio Ltd. (ENTX), combining market capitalization with net debt. By analyzing the company's actual market price, an investor sees the factual cost of acquiring the business net of cash. The dynamics of this metric reveal speculative deviations from fundamental value. For Entera Bio Ltd. (ENTX), this valuation depends directly on the success of oral protein delivery and patent purity. Growth in this metric signals market expectations currently priced in regarding the efficacy of new therapy forms.